TY - JOUR
T1 - Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia
AU - Zargari, Omid
AU - Kimyai-Asadi, Arash
AU - Jafroodi, Maryam
PY - 2004/11
Y1 - 2004/11
N2 - Although the cutaneous effects of hydroxyurea have been described for patients with sickle cell anemia, myeloproliferativo disorders, and psoriasis, there are no reports of cutaneous adverse effects from hydroxyurea when used for patients with intermediate thalassemia. Therefore 43 patients with intermediate thalassemia treated with hydroxyurea were examined by a dermatologist, and pertinent cutaneous findings were recorded. These patients had received hydroxyurea for a mean of 15.5 months. Nineteen had cutaneous hyperpigmentation, eight had xerosis, and three were found to have one café au lait macule each. Eleven patients had nail abnormalities, including nail ridging, partial leukonychia, and longitudinal melanonychia. There were no cases of leg ulceration. It was concluded that the risk of developing leg ulcers and pigmentary disorders appears to be related to the underlying disease being treated, as well as to a patient's age, gender, and pigmentation.
AB - Although the cutaneous effects of hydroxyurea have been described for patients with sickle cell anemia, myeloproliferativo disorders, and psoriasis, there are no reports of cutaneous adverse effects from hydroxyurea when used for patients with intermediate thalassemia. Therefore 43 patients with intermediate thalassemia treated with hydroxyurea were examined by a dermatologist, and pertinent cutaneous findings were recorded. These patients had received hydroxyurea for a mean of 15.5 months. Nineteen had cutaneous hyperpigmentation, eight had xerosis, and three were found to have one café au lait macule each. Eleven patients had nail abnormalities, including nail ridging, partial leukonychia, and longitudinal melanonychia. There were no cases of leg ulceration. It was concluded that the risk of developing leg ulcers and pigmentary disorders appears to be related to the underlying disease being treated, as well as to a patient's age, gender, and pigmentation.
UR - http://www.scopus.com/inward/record.url?scp=10644277061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10644277061&partnerID=8YFLogxK
U2 - 10.1111/j.0736-8046.2004.21603.x
DO - 10.1111/j.0736-8046.2004.21603.x
M3 - Article
C2 - 15575845
AN - SCOPUS:10644277061
SN - 0736-8046
VL - 21
SP - 633
EP - 635
JO - Pediatric Dermatology
JF - Pediatric Dermatology
IS - 6
ER -